David R. Epstein | Advisor to the Managing Partner

David Epstein is an advisor to J.P. Morgan Life Sciences Private Capital.

He was most recently chief executive officer of Seagen, a company that discovers, develops, manufactures, and commercializes targeted cancer therapeutics with antibody-drug conjugates at its core.

During his tenure at Seagen, its portfolio of innovative targeted cancer medicines grew significantly and he ultimately led the merger of Seagen with Pfizer.

Epstein is also a board member at Valo Health, a company using AI and machine learning technology to reimagine drug discovery and development.

From 2010-2016, he served as CEO of Novartis Pharmaceuticals, a division of Novartis AG. Previously, Epstein started and led Novartis’ Oncology and Molecular Diagnostic units.

Over the course of his career, he led the development and commercialization of over 30 new molecular entities, including major breakthroughs such as Gleevec, Tasigna, Gilenya, Afinitor, Cosentyx and Entresto. His teams gained approval for over 100 new indications and launched three Prix Galien award winning medicines.